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Chemokines are a family of cytokines that exhibit selective chemoattractant properties 
for target leukocytes, including CD4+ T lymphocytes, and play a significant role 
leukocyte migration. However, a target leukocyte can only respond to a chemokine if 
it expresses the cognate receptor(s). Recent studies have demonstrated alterations in 
both chemokine and chemokine receptor expression patterns in the CNS during 
experimental autoimmune encephalomyelitis (EAE), a model for MUltiple Sclerosis. 
Accordingly, the aim of the research presented in this thesis was to investigate 
chemokine receptor regulation and function on CD4+ T lymphocytes during T cell­
mediated central nervous system (CNS) inflammation in vivo. In the proteolipid 
protein (PLP)-induced model of EAE. two inflammatory (CXCR3 and CCR5) and 
one supposedly homeostatic (CXCR4) chemokine receptors were up regulated on 
CD4+ T cells during antigen-dependent clonal selection in the draining lymph nodes. 
As the CD4+ T cells migrated through the blood and into the CNS tissue, expression 
of these receptors remained elevated such that, at the peak of clinical disease, the 
majority of neuroantigen-specific CD4+ T cells in the CNS expressed elevated levels 
of CXCR4. CXCR3 and CCR5. Detailed characterisation of these receptors revealed 
that upregulation occurred in co-ordination with cellular division. 
Subsequent experiments were performed in order to determine the biological 
consequences of specific chemokine/receptor interactions during EAE. Amino 
terminal modifications of chemokines, which convert agonists to antagonists, have 
previously shown to interfere with ligand/receptor interactions during 
, 
inflammation. Therefore, a series of synthetic N-terminal chemokine mutants were 
initially tested in vitro for their ability to act as antagonists in preventing the migration 
of neuroantigen-activated lymphocytes to ligands of the receptors CXCR4, CXCR3 
and CCR5. These analyses revealed that the synthetic mutants SDF-l P2G. I-TAC 4­
79 and R ANTES 9-68 possessed potent antagonistic capacities. Following EAE 
induction, treatment every second day with the antagonists until day 15 resulted in a 
significant decrease in the severity of the neurological symptoms of EAE. 
Histological analyses demonstrated that the reduction in disease severity 
corresponded with a reduced number of inflammatory infiltrates in the spinal cords of 
antagonist-treated mice at peak clinical disease compared with control-treated mice. 
been 
" ",  .
The ability to separate the disease process into two separate phases (sensitisation and 
effector) using adoptive transfer experiments provided a means to investigate the 
temporal and spatial control that specific chemokine/receptor interactions exerted 
during the pathogenesis of EAE. Accordingly, a series of ex vivo proliferation assays 
and adoptive transfer experiments were conducted. From these experiments, a 
potential role for the SDF-lICXCR4 interaction was identified in the sensistisation 
phase of the disease. These results indicated that SDF-lICXCL12 and CXCR4 
interactions not only play a role in homeostasis, but may also provide costimulatory 
signals to antigen-stimulated CD4+ T cells. Convere1y, roles for 1-TAC/CXCR3 and 
RANTES/CCR5 interactions, but not SDF-lICXCR4 interactions were identified in 
the effector phase of EAE. Collectively, the results generated in the present thesis, 
together with those from other studies, enabled the construction of a model detailing 
the temporal and spatial parameters of chemokine/chemokine receptor regulation of 
CD4+ T cell activation and migration during a CD4+ T cell-mediated immune 
response in the CNS. 
" 
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